1) 堀誠治:副作用.抗菌薬投与の科学(砂川慶介,戸塚恭一編),医薬ジャーナル社,pp58-72, 1998
2) 堀誠治:抗菌薬の副作用とその発現機序―濃度依存的な副作用を中心に.日化療会誌 52:293-303, 2004
3) Nicolau DP:Optimizing outcome with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother 9:292-296, 2003
4) Andes D, Craig WA:Understanding Pharmacokinetics and Pharmacodynamics:Application to the antimicrobial formulary decision precess. Antibiotic Optimization (Owens RC Jr, Ambrose PG, Nightingale CH, eds). Marcel Dekker, New York, 2005
5) 堀誠治:副作用・相互作用を考慮した投与計画.化学療法の領域 19:528-538, 2003
6) 土井邦雄:腎毒性.医薬品の安全性(長尾拓編),南山堂,pp170-177, 2004
7) 堀誠治:副作用と使い方.Mebio 17(10):70-78, 2000
8) Gilbert DN:Aminoglycosides. Mandell, Douglas, and Bennett's Principle and Practice of Infectious Diseases (Mandell GL, Bennett JE, Dolin R, eds), Chuchill Livingstone, Philadelphia, pp307-336, 2000
9) Quintiliani R Jr, Quintiliani R, Nightingale CH:Aminoglycosides. Infectious Diseases 2nd ed. (Cohen J, Powderly WG, et al, eds), Mosby, Edinburgh, pp1809-1818, 2004
10) 清水喜八郎,相川直樹,谷川原祐介,他:本邦における抗MRSA薬arbecacinを中心とした使用実態.日化療会誌 51:717-730, 2003
11) 堀岡正義:調剤学総論(第5版),南山堂,2001
12) Rahman H, Smith L:Glycopeptides. Infectious Diseases (Armstrong D, Cohen J, Berky SF, et al, eds), Mosby, London, pp101-106, 1999
13) 草野展周:ポリペプチド系薬.JIM 12:1040-1042, 2002
14) Calandra G, Lyock E, Carrigan J, et al:Factors predisposing to seizures in seriously ill infected patients receiving antibiotics. Experience with imipenem/cilastatin. Am J Med 84:911-918, 1988
15) Shimada J, Hori S, Kanemitsu K, et al:A comparative study on the convulsant activity of carbapenems and beta-lactams. Drugs Exptl Clin Res 18:377-381, 1992
17) 厚生労働省:医薬品副作用情報No.188, 2003
18) 玉山俊行,田中逸,斎藤篤:Gatofloxacinの血糖値異常副作用発現に関する調査成績―患者背景およびリスク要因の分析.日化療会誌 52:521-529, 2004